Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication

Affiliations

¹ Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont and Maggiore Charity Hospital, 28100 Novara, Italy.
² Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont and Maggiore Charity Hospital, 28100 Novara, Italy. Electronic address: gianluca.gaidano@med.uniupo.it.

Comment

Lorenzo De Paoli et al. Lancet Oncol. 2017 Feb.

. 2017 Feb;18(2):163-164.

doi: 10.1016/S1470-2045(17)30017-7. Epub 2017 Jan 13.

¹ Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont and Maggiore Charity Hospital, 28100 Novara, Italy.
² Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont and Maggiore Charity Hospital, 28100 Novara, Italy. Electronic address: gianluca.gaidano@med.uniupo.it.

No abstract available

Comment on

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Seymour JF, et al. Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13. Lancet Oncol. 2017. PMID: 28089635 Free PMC article. Clinical Trial.